Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-01

AUTHORS

Gabriel Rogers, Ruth Garside, Stuart Mealing, Martin Pitt, Rob Anderson, Matthew Dyer, Ken Stein, Margaret Somerville

ABSTRACT

BackgroundHigh-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively. The intracranial implantation of carmustine wafers (BCNU-W), which delivers chemotherapy directly to the affected area, may prolong survival in this population. However, no attention has yet been paid to the economic implications of BCNU-W in this setting.ObjectiveTo investigate the cost effectiveness of BCNU-W as an adjunct to surgery followed by radiotherapy, compared with surgery plus radiotherapy alone. Newly diagnosed, operable grade III and IV gliomas in a population with a mean age of 55 years were considered.MethodsA Markov cost-utility model was developed in Microsoft® Excel, adopting a UK NHS perspective. Transition probabilities and cost data (year 2004 values) were obtained from published literature or expert opinion. The model incorporated utility values, obtained from members of the public, reflecting the quality of life associated with high-grade glioma. The effects of uncertainty were explored through extensive one-way and probabilistic sensitivity analysis.ResultsSurgery with the implantation of BCNU-W followed by radiotherapy costs £54 500 per additional QALY gained when compared with surgery plus radiotherapy alone. Probabilistic sensitivity analysis shows a <10% probability that BCNU-W would be considered cost effective at a willingness-to-pay threshold of £30 000 per QALY. Although model outputs were sensitive to alterations in several key parameters, the incremental cost effectiveness of the intervention remained above £30 000 per QALY in all analyses.ConclusionCompared with usual care for the treatment of newly diagnosed high-grade gliomas, BCNU-W is unlikely to be considered a cost-effective use of healthcare resources when judged by the standards commonly adopted in England and Wales. However, the dreadful prognosis of the condition and the paucity of alternative therapies are additional issues that healthcare commissioners may choose to take into account when considering an adoption decision. More... »

PAGES

33-44

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00019053-200826010-00004

DOI

http://dx.doi.org/10.2165/00019053-200826010-00004

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010188101

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18088157


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carmustine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Implants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Econometric", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rogers", 
        "givenName": "Gabriel", 
        "id": "sg:person.01174312663.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garside", 
        "givenName": "Ruth", 
        "id": "sg:person.01024532450.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024532450.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mealing", 
        "givenName": "Stuart", 
        "id": "sg:person.01005620411.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005620411.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pitt", 
        "givenName": "Martin", 
        "id": "sg:person.01332202761.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332202761.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anderson", 
        "givenName": "Rob", 
        "id": "sg:person.01226303006.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226303006.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dyer", 
        "givenName": "Matthew", 
        "id": "sg:person.01354421506.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354421506.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Ken", 
        "id": "sg:person.01054372611.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.8391.3", 
          "name": [
            "Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Somerville", 
        "givenName": "Margaret", 
        "id": "sg:person.01037253661.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037253661.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1005790632126", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005160698", 
          "https://doi.org/10.1023/a:1005790632126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-002-0392-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075217885", 
          "https://doi.org/10.1007/s00520-002-0392-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00435979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008379504", 
          "https://doi.org/10.1007/bf00435979"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01060217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026284430", 
          "https://doi.org/10.1007/bf01060217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00701-005-0707-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034937505", 
          "https://doi.org/10.1007/s00701-005-0707-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01", 
    "datePublishedReg": "2008-01-01", 
    "description": "BackgroundHigh-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively. The intracranial implantation of carmustine wafers (BCNU-W), which delivers chemotherapy directly to the affected area, may prolong survival in this population. However, no attention has yet been paid to the economic implications of BCNU-W in this setting.ObjectiveTo investigate the cost effectiveness of BCNU-W as an adjunct to surgery followed by radiotherapy, compared with surgery plus radiotherapy alone. Newly diagnosed, operable grade III and IV gliomas in a population with a mean age of 55 years were considered.MethodsA Markov cost-utility model was developed in Microsoft\u00ae Excel, adopting a UK NHS perspective. Transition probabilities and cost data (year 2004 values) were obtained from published literature or expert opinion. The model incorporated utility values, obtained from members of the public, reflecting the quality of life associated with high-grade glioma. The effects of uncertainty were explored through extensive one-way and probabilistic sensitivity analysis.ResultsSurgery with the implantation of BCNU-W followed by radiotherapy costs \u00a354 500 per additional QALY gained when compared with surgery plus radiotherapy alone. Probabilistic sensitivity analysis shows a <10% probability that BCNU-W would be considered cost effective at a willingness-to-pay threshold of \u00a330 000 per QALY. Although model outputs were sensitive to alterations in several key parameters, the incremental cost effectiveness of the intervention remained above \u00a330 000 per QALY in all analyses.ConclusionCompared with usual care for the treatment of newly diagnosed high-grade gliomas, BCNU-W is unlikely to be considered a cost-effective use of healthcare resources when judged by the standards commonly adopted in England and Wales. However, the dreadful prognosis of the condition and the paucity of alternative therapies are additional issues that healthcare commissioners may choose to take into account when considering an adoption decision.", 
    "genre": "article", 
    "id": "sg:pub.10.2165/00019053-200826010-00004", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.9713426", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "26"
      }
    ], 
    "keywords": [
      "probabilistic sensitivity analyses", 
      "incremental cost effectiveness", 
      "cost-utility model", 
      "UK NHS perspective", 
      "effect of uncertainty", 
      "cost effectiveness", 
      "sensitivity analysis", 
      "economic implications", 
      "additional QALY", 
      "adoption decisions", 
      "cost-effective use", 
      "cost data", 
      "QALY", 
      "NHS perspective", 
      "utility values", 
      "radiotherapy costs", 
      "healthcare resources", 
      "cost", 
      "one-way", 
      "willingness", 
      "additional issues", 
      "decisions", 
      "uncertainty", 
      "model", 
      "healthcare commissioners", 
      "model output", 
      "output", 
      "implications", 
      "resources", 
      "usual care", 
      "probability", 
      "analysis", 
      "perspective", 
      "literature", 
      "public", 
      "expert opinion", 
      "issues", 
      "key parameters", 
      "commissioners", 
      "account", 
      "effectiveness", 
      "Microsoft", 
      "England", 
      "Excel", 
      "quality of life", 
      "attention", 
      "standards", 
      "data", 
      "values", 
      "opinion", 
      "setting", 
      "quality", 
      "Wales", 
      "effect", 
      "threshold", 
      "population", 
      "members", 
      "years", 
      "high-grade gliomas", 
      "care", 
      "intervention", 
      "area", 
      "transition", 
      "use", 
      "life", 
      "Treatment of Newly", 
      "aggressive brain tumor", 
      "conditions", 
      "carmustine wafers", 
      "grade III", 
      "mean age", 
      "dreadful prognosis", 
      "paucity", 
      "alternative therapies", 
      "carmustine implants", 
      "brain tumors", 
      "intracranial implantation", 
      "gliomas", 
      "BCNU", 
      "radiotherapy", 
      "Newly", 
      "surgery", 
      "parameters", 
      "treatment", 
      "implantation", 
      "affected area", 
      "chemotherapy", 
      "ResultsSurgery", 
      "prognosis", 
      "tumors", 
      "ObjectiveTo", 
      "age", 
      "therapy", 
      "adjunct", 
      "survival", 
      "alterations", 
      "implants", 
      "wafers"
    ], 
    "name": "Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas", 
    "pagination": "33-44", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010188101"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00019053-200826010-00004"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18088157"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00019053-200826010-00004", 
      "https://app.dimensions.ai/details/publication/pub.1010188101"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_478.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.2165/00019053-200826010-00004"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00019053-200826010-00004'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00019053-200826010-00004'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00019053-200826010-00004'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00019053-200826010-00004'


 

This table displays all metadata directly associated to this object as RDF triples.

282 TRIPLES      21 PREDICATES      142 URIs      129 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00019053-200826010-00004 schema:about N0d444c1be40640a1a46558b691a11afe
2 N1a979aea1ef94332aed4cfb7142c7230
3 N2085efc304a3496097bb4072c2148ff9
4 N2c2d90d4035a45fab471a181f68f56e0
5 N332f5470ed014269ba861cc99b187236
6 N36635f1f452347aba2974d896d871c7b
7 N40c61049b50248da8c704422a1d70cb2
8 N7a7c8b32717d4db397b20d72e1224110
9 N7cd9352d0fa04070b44c62fbaa80b35a
10 Nb8ca066e2ba245b7bff6744a4de18743
11 Nbc46f4ac77254e9394f1d9932031a3db
12 Neeae33e2f61e44b784a5790371bc92b3
13 Nf73b2c4b100940b49060047bd6f68fa9
14 anzsrc-for:14
15 anzsrc-for:1402
16 schema:author N3b5381d164ef4a869164fd4287508aba
17 schema:citation sg:pub.10.1007/bf00435979
18 sg:pub.10.1007/bf01060217
19 sg:pub.10.1007/s00520-002-0392-x
20 sg:pub.10.1007/s00701-005-0707-z
21 sg:pub.10.1023/a:1005790632126
22 schema:datePublished 2008-01
23 schema:datePublishedReg 2008-01-01
24 schema:description BackgroundHigh-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively. The intracranial implantation of carmustine wafers (BCNU-W), which delivers chemotherapy directly to the affected area, may prolong survival in this population. However, no attention has yet been paid to the economic implications of BCNU-W in this setting.ObjectiveTo investigate the cost effectiveness of BCNU-W as an adjunct to surgery followed by radiotherapy, compared with surgery plus radiotherapy alone. Newly diagnosed, operable grade III and IV gliomas in a population with a mean age of 55 years were considered.MethodsA Markov cost-utility model was developed in Microsoft® Excel, adopting a UK NHS perspective. Transition probabilities and cost data (year 2004 values) were obtained from published literature or expert opinion. The model incorporated utility values, obtained from members of the public, reflecting the quality of life associated with high-grade glioma. The effects of uncertainty were explored through extensive one-way and probabilistic sensitivity analysis.ResultsSurgery with the implantation of BCNU-W followed by radiotherapy costs £54 500 per additional QALY gained when compared with surgery plus radiotherapy alone. Probabilistic sensitivity analysis shows a <10% probability that BCNU-W would be considered cost effective at a willingness-to-pay threshold of £30 000 per QALY. Although model outputs were sensitive to alterations in several key parameters, the incremental cost effectiveness of the intervention remained above £30 000 per QALY in all analyses.ConclusionCompared with usual care for the treatment of newly diagnosed high-grade gliomas, BCNU-W is unlikely to be considered a cost-effective use of healthcare resources when judged by the standards commonly adopted in England and Wales. However, the dreadful prognosis of the condition and the paucity of alternative therapies are additional issues that healthcare commissioners may choose to take into account when considering an adoption decision.
25 schema:genre article
26 schema:isAccessibleForFree false
27 schema:isPartOf N3ecb2eaff6ce4cefa7640edf64b1398b
28 Nc8fe9341ce67483285875413d2cd8172
29 sg:journal.1102812
30 schema:keywords BCNU
31 England
32 Excel
33 Microsoft
34 NHS perspective
35 Newly
36 ObjectiveTo
37 QALY
38 ResultsSurgery
39 Treatment of Newly
40 UK NHS perspective
41 Wales
42 account
43 additional QALY
44 additional issues
45 adjunct
46 adoption decisions
47 affected area
48 age
49 aggressive brain tumor
50 alterations
51 alternative therapies
52 analysis
53 area
54 attention
55 brain tumors
56 care
57 carmustine implants
58 carmustine wafers
59 chemotherapy
60 commissioners
61 conditions
62 cost
63 cost data
64 cost effectiveness
65 cost-effective use
66 cost-utility model
67 data
68 decisions
69 dreadful prognosis
70 economic implications
71 effect
72 effect of uncertainty
73 effectiveness
74 expert opinion
75 gliomas
76 grade III
77 healthcare commissioners
78 healthcare resources
79 high-grade gliomas
80 implantation
81 implants
82 implications
83 incremental cost effectiveness
84 intervention
85 intracranial implantation
86 issues
87 key parameters
88 life
89 literature
90 mean age
91 members
92 model
93 model output
94 one-way
95 opinion
96 output
97 parameters
98 paucity
99 perspective
100 population
101 probabilistic sensitivity analyses
102 probability
103 prognosis
104 public
105 quality
106 quality of life
107 radiotherapy
108 radiotherapy costs
109 resources
110 sensitivity analysis
111 setting
112 standards
113 surgery
114 survival
115 therapy
116 threshold
117 transition
118 treatment
119 tumors
120 uncertainty
121 use
122 usual care
123 utility values
124 values
125 wafers
126 willingness
127 years
128 schema:name Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas
129 schema:pagination 33-44
130 schema:productId N3f3faded4104460782997fc3a7d11ee9
131 N53ecc1dd12b347b6854c02dca559441f
132 Ne5b1493612bc49e7837f8f41388eaae6
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010188101
134 https://doi.org/10.2165/00019053-200826010-00004
135 schema:sdDatePublished 2022-09-02T15:52
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher Nfd3dba7c0e2a41a1901f7b7d5dce03b2
138 schema:url https://doi.org/10.2165/00019053-200826010-00004
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N0d444c1be40640a1a46558b691a11afe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Cohort Studies
144 rdf:type schema:DefinedTerm
145 N175ee1a9727b4ea4819bcfa0911b9bae rdf:first sg:person.01332202761.06
146 rdf:rest Nd46400bf533848c38b86fa0cf4e32ae2
147 N1a979aea1ef94332aed4cfb7142c7230 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N2085efc304a3496097bb4072c2148ff9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Quality of Life
152 rdf:type schema:DefinedTerm
153 N2c2d90d4035a45fab471a181f68f56e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Drug Implants
155 rdf:type schema:DefinedTerm
156 N332f5470ed014269ba861cc99b187236 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Neoplasm Staging
158 rdf:type schema:DefinedTerm
159 N36635f1f452347aba2974d896d871c7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Middle Aged
161 rdf:type schema:DefinedTerm
162 N3b5381d164ef4a869164fd4287508aba rdf:first sg:person.01174312663.64
163 rdf:rest N8a40c52ee95d435895928bc4158694f5
164 N3ecb2eaff6ce4cefa7640edf64b1398b schema:issueNumber 1
165 rdf:type schema:PublicationIssue
166 N3f3faded4104460782997fc3a7d11ee9 schema:name doi
167 schema:value 10.2165/00019053-200826010-00004
168 rdf:type schema:PropertyValue
169 N40c61049b50248da8c704422a1d70cb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Glioma
171 rdf:type schema:DefinedTerm
172 N53ecc1dd12b347b6854c02dca559441f schema:name pubmed_id
173 schema:value 18088157
174 rdf:type schema:PropertyValue
175 N6170b5de61b049e195ca6f6c353a925c rdf:first sg:person.01354421506.26
176 rdf:rest N9bde6676fde6423bad0e43991148eaea
177 N7a7c8b32717d4db397b20d72e1224110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Brain Neoplasms
179 rdf:type schema:DefinedTerm
180 N7cd9352d0fa04070b44c62fbaa80b35a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antineoplastic Agents
182 rdf:type schema:DefinedTerm
183 N8a40c52ee95d435895928bc4158694f5 rdf:first sg:person.01024532450.24
184 rdf:rest Ne6dabd050a5445fea8518097bab0dc38
185 N9bde6676fde6423bad0e43991148eaea rdf:first sg:person.01054372611.40
186 rdf:rest Ndb806c1ead4b4efa8576827ad717bd91
187 Nb8ca066e2ba245b7bff6744a4de18743 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Chemotherapy, Adjuvant
189 rdf:type schema:DefinedTerm
190 Nbc46f4ac77254e9394f1d9932031a3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Cost-Benefit Analysis
192 rdf:type schema:DefinedTerm
193 Nc8fe9341ce67483285875413d2cd8172 schema:volumeNumber 26
194 rdf:type schema:PublicationVolume
195 Nd46400bf533848c38b86fa0cf4e32ae2 rdf:first sg:person.01226303006.44
196 rdf:rest N6170b5de61b049e195ca6f6c353a925c
197 Ndb806c1ead4b4efa8576827ad717bd91 rdf:first sg:person.01037253661.56
198 rdf:rest rdf:nil
199 Ne5b1493612bc49e7837f8f41388eaae6 schema:name dimensions_id
200 schema:value pub.1010188101
201 rdf:type schema:PropertyValue
202 Ne6dabd050a5445fea8518097bab0dc38 rdf:first sg:person.01005620411.90
203 rdf:rest N175ee1a9727b4ea4819bcfa0911b9bae
204 Neeae33e2f61e44b784a5790371bc92b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Models, Econometric
206 rdf:type schema:DefinedTerm
207 Nf73b2c4b100940b49060047bd6f68fa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Carmustine
209 rdf:type schema:DefinedTerm
210 Nfd3dba7c0e2a41a1901f7b7d5dce03b2 schema:name Springer Nature - SN SciGraph project
211 rdf:type schema:Organization
212 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
213 schema:name Economics
214 rdf:type schema:DefinedTerm
215 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
216 schema:name Applied Economics
217 rdf:type schema:DefinedTerm
218 sg:grant.9713426 http://pending.schema.org/fundedItem sg:pub.10.2165/00019053-200826010-00004
219 rdf:type schema:MonetaryGrant
220 sg:journal.1102812 schema:issn 1170-7690
221 1179-2027
222 schema:name PharmacoEconomics
223 schema:publisher Springer Nature
224 rdf:type schema:Periodical
225 sg:person.01005620411.90 schema:affiliation grid-institutes:grid.8391.3
226 schema:familyName Mealing
227 schema:givenName Stuart
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005620411.90
229 rdf:type schema:Person
230 sg:person.01024532450.24 schema:affiliation grid-institutes:grid.8391.3
231 schema:familyName Garside
232 schema:givenName Ruth
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024532450.24
234 rdf:type schema:Person
235 sg:person.01037253661.56 schema:affiliation grid-institutes:grid.8391.3
236 schema:familyName Somerville
237 schema:givenName Margaret
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037253661.56
239 rdf:type schema:Person
240 sg:person.01054372611.40 schema:affiliation grid-institutes:grid.8391.3
241 schema:familyName Stein
242 schema:givenName Ken
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01054372611.40
244 rdf:type schema:Person
245 sg:person.01174312663.64 schema:affiliation grid-institutes:grid.8391.3
246 schema:familyName Rogers
247 schema:givenName Gabriel
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01174312663.64
249 rdf:type schema:Person
250 sg:person.01226303006.44 schema:affiliation grid-institutes:grid.8391.3
251 schema:familyName Anderson
252 schema:givenName Rob
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226303006.44
254 rdf:type schema:Person
255 sg:person.01332202761.06 schema:affiliation grid-institutes:grid.8391.3
256 schema:familyName Pitt
257 schema:givenName Martin
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332202761.06
259 rdf:type schema:Person
260 sg:person.01354421506.26 schema:affiliation grid-institutes:grid.8391.3
261 schema:familyName Dyer
262 schema:givenName Matthew
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354421506.26
264 rdf:type schema:Person
265 sg:pub.10.1007/bf00435979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008379504
266 https://doi.org/10.1007/bf00435979
267 rdf:type schema:CreativeWork
268 sg:pub.10.1007/bf01060217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026284430
269 https://doi.org/10.1007/bf01060217
270 rdf:type schema:CreativeWork
271 sg:pub.10.1007/s00520-002-0392-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1075217885
272 https://doi.org/10.1007/s00520-002-0392-x
273 rdf:type schema:CreativeWork
274 sg:pub.10.1007/s00701-005-0707-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1034937505
275 https://doi.org/10.1007/s00701-005-0707-z
276 rdf:type schema:CreativeWork
277 sg:pub.10.1023/a:1005790632126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005160698
278 https://doi.org/10.1023/a:1005790632126
279 rdf:type schema:CreativeWork
280 grid-institutes:grid.8391.3 schema:alternateName Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
281 schema:name Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School, Universities of Exeter and Plymouth, Noy Scott House, Barrack Road, EX2 5DW, Exeter, UK
282 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...